Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy

References

• Morrison V. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma. 2009;9:365–70. doi:10.3816/CLM.2009.n.071. PMID:19858055.
   PubMedGoogle Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126:573–81. doi:10.1182/blood-2015-03-567388. PMID:26084672.
   PubMed Web of Science ®Google Scholar
• Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, et al. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. Int J Cancer. 2014;135:2370–9. doi:10.1002/ijc.28884. PMID:24723150.
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Dieu R Le, Blum W, Byrd JC, Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118:2427–37. PMID:18551193.
   PubMed Web of Science ®Google Scholar
• Christopoulos P, Pfeifer D, Bartholomé K, Follo M, Timmer J, Fisch P, Veelken H. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood. 2011;117:3836–46. doi:10.1182/blood-2010-07-299321. PMID:21270444.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E, Viñolas N. Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance. Cancer. 1988;61:279–83. doi:10.1002/1097-0142(19880115)61:2%3c279::AID-CNCR2820610215/3e3.0.CO;2-4. PMID:2446736.
   PubMed Web of Science ®Google Scholar
• Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17:75–80. doi:10.1111/j.1365-2257.1995.tb00322.x. PMID:7621634.
   PubMedGoogle Scholar
• Hartkamp A, Mulder AH., Rijkers G, van Velzen-Blad H, Biesma D. Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine. 2001;19:1671–7. doi:10.1016/S0264-410X(00)00409-6. PMID:11166890.
   PubMed Web of Science ®Google Scholar
• Sinsalo M, Aittoniemi J, Käyhty H, Vilpo J. Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma. 2002;43:1967–9. doi:10.1080/1042819021000015916. PMID:12481893.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, et al. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia. J Clin Oncol. 2005;23:4079–88. doi:10.1200/JCO.2005.12.051. PMID:15767648.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Fink A, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–74. doi:10.1016/S0140-6736(10)61381-5. PMID:20888994.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med. 2015;373:2425–37. doi:10.1056/NEJMoa1509388. PMID:26639149.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014;15:48–58. doi:10.1016/S1470-2045(13)70513-8. PMID:24332241.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N Engl J Med. 2014;371:213–23. doi:10.1056/NEJMoa1400376. PMID:24881631.
   PubMed Web of Science ®Google Scholar
• Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010;24:1310–6. doi:10.1038/leu.2010.89. PMID:20463751.
   PubMed Web of Science ®Google Scholar
• Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do K-A, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975–80. doi:10.1182/blood-2008-02-140582. PMID:18411418.
   PubMed Web of Science ®Google Scholar
• Schliffke S, Akyüz N, Ford CT, Mährle T, Thenhausen T, Krohn-Grimberghe A, Knop S, Bokemeyer C, Binder M. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. Leukemia. 2016;30:2232–4. doi:10.1038/leu.2016.157. PMID:27220665.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446–60. doi:10.1002/ajh.23979. PMID:25908509.
   PubMed Web of Science ®Google Scholar
• Eichhorst B, Fink A-M, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–42. doi:10.1016/S1470-2045(16)30051-1. PMID:27216274.
   PubMed Web of Science ®Google Scholar
• Dubovsky JA, Beckwith KA, Natarajan G, Woyach J, Jaglowski S, Zhong Y, Hessler JD, Liu T-M, Chang BY, Larkin KM, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–49. doi:10.1182/blood-2013-06-507947. PMID:23886836.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee Y, Gunti S, Lipsky A, Herman S, Salem D, Stetler-Stevenson M, Yuan C, Kardava L, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126:2213–9. doi:10.1182/blood-2015-04-639203. PMID:26337493.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–506. doi:10.1182/blood-2014-10-606038. PMID:25700432.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, et al. Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. J Clin Oncol. 2010;28:1749–55. doi:10.1200/JCO.2009.25.3187. PMID:20194866.
   PubMed Web of Science ®Google Scholar
• Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94:2033–9. doi:10.1002/cncr.0680. PMID:11932906.
   PubMed Web of Science ®Google Scholar
• Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–3. doi:10.1182/blood-2016-06-722991. PMID:27503501.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, O'Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727–32. doi:10.1182/blood-2013-11-538116. PMID:24705492.
   PubMed Web of Science ®Google Scholar
• Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford CT, et al. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. Int J Cancer. 2017;140:2535–44. doi:10.1002/ijc.30549. PMID:27925177.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Langerak AW, Brüggemann M, Evans PAS, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, García-Sanz R, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317. doi:10.1038/sj.leu.2403202. PMID:14671650.
   PubMed Web of Science ®Google Scholar
• Thiele B, Kloster M, Alawi M, Indenbirken D, Trepel M, Grundhoff A, Binder M. Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. Blood. 2014;123:3618–21. doi:10.1182/blood-2014-02-556746. PMID:24753536.
   PubMed Web of Science ®Google Scholar
• Bolotin DA, Poslavsky S, Mitrophanov I, Shugay M, Mamedov IZ, Putintseva E V, Chudakov DM. MiXCR: software for comprehensive adaptive immunity profiling. Nat Methods. 2015;12:380–1. doi:10.1038/nmeth.3364. PMID:25924071.
   PubMed Web of Science ®Google Scholar
• Jost L. Partitioning diversity into independent alpha and beta components. Ecology. 2007;88:2427–39. doi:10.1890/06-1736.1. PMID:18027744.
   PubMed Web of Science ®Google Scholar
• Kirsch I, Vignali M, Robins H. T-cell receptor profiling in cancer. Mol Oncol. 2015;9:2063–70. doi:10.1016/j.molonc.2015.09.003. PMID:26404496.
   PubMed Web of Science ®Google Scholar
• Erkeller-Yuksel FM, Deneys V, Yuksel B, Hannet I, Hulstaert F, Hamilton C, Mackinnon H, Stokes LT, Munhyeshuli V, Vanlangendonck F. Age-related changes in human blood lymphocyte subpopulations. J Pediatr. 1992;120:216–22. doi:10.1016/S0022-3476(05)80430-5. PMID:1735817.
   PubMed Web of Science ®Google Scholar
• Jain N, O'Brien S. Initial treatment of CLL: integrating biology and functional status. Blood. 2015;126:463–70. doi:10.1182/blood-2015-04-585067. PMID:26065656.
   PubMed Web of Science ®Google Scholar
• Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2016;374:311–22. doi:10.1056/NEJMoa1513257. PMID:26639348.
   PubMed Web of Science ®Google Scholar
• García Muñoz R, Izquierdo-Gil A, Muñoz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol. 2014;93:1879–87. doi:10.1007/s00277-014-2135-8. PMID:24951124.
   PubMed Web of Science ®Google Scholar
• Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014;32:1830–9. doi:10.1200/JCO.2013.53.1046. PMID:24778403.
   PubMed Web of Science ®Google Scholar
• Mitsuiki N, Yang X, Bartol SJW, Grosserichter C. Mutations in Bruton’ s tyrosine kinase impair IgA responses. Int J Hematol. 2015;101:305–13. doi:10.1007/s12185-015-1732-1. PMID:25589397.
   PubMed Web of Science ®Google Scholar
• Kil LP, de Bruijn MJW, van Nimwegen M, Corneth OBJ, van Hamburg JP, Dingjan GM, Thaiss F, Rimmelzwaan GF, Elewaut D, Delsing D, et al. Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood. 2012;119:3744–56. doi:10.1182/blood-2011-12-397919. PMID:22383797.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Davis SD, Wedgwood RJ. Immunologic responses to bacteriophage φX 174 in immunodeficiency diseases. J Clin Invest. 1971;50:2559–68. doi:10.1172/JCI106756. PMID:5129308.
   PubMed Web of Science ®Google Scholar